Full Press Release Details
InspireMD Hires Vice President of
Corporate Development
Former Covidien Executive, Gwen Bame,
Focus on Strategic Programs Worldwide
TEL AVIV, Israel, APR. 19 -
InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) said Gwen K. Bame has joined the Company
as Vice President of Corporate Development, reporting directly to Alan Milinazzo, President and CEO.
new position created to strengthen our executive team with a clear focus on executing strategic programs and partnerships designed
to meet our ambitious global growth objectives, said Mr. Milinazzo. "Gwen has the right blend of industry and management
experience and we are delighted to welcome her to InspireMD."
Ms. Bame's responsibilities
will include identifying and negotiating in/out licensing agreements, analyzing strategic partnerships and structuring of joint
ventures on a worldwide basis.
Ms. Bame joined Covidien
in 2009 upon its acquisition of Aspect Medical Systems, where she held various sales and marketing leadership positions during
her tenure. She led significant market development programs directly and via strategic partnerships which drove adoption of the
Prior to her time at
Covidien, Ms. Bame spent 12 years with Boston Scientific in the cardiology business in sales, marketing and corporate accounts.
During her career at BSC, she negotiated roughly $350 million in contracted business across multiple business units.
About InspireMD, Inc.
InspireMD is a medical
device company focusing on the development and commercialization of its proprietary stent system technology, MGuard . InspireMD
intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock
is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains "forward-looking
statements." Such statements may be preceded by the words "intends," "may," "will," "plans,"
"expects," "anticipates," "projects," "predicts," "estimates," "aims,"
"believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results
or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi)
our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual
property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the
fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising
may be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in multiple foreign jurisdictions,
exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance
with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and
the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission (SEC), including the Company's Transition Report on Form 10-K/T and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov.
The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information,
future events or otherwise.
For additional information: